BIA
EWTX icon

Bell Investment Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Bell Investment Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$610 Buy
+15
New +$517 ﹤0.01% 1669

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bell Investment Advisors's EWTX Position: Q2 2026 in Review

Bell Investment Advisors opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 15 shares worth $610. The stake represents ﹤0.01% of the portfolio and ranks #1669 among its holdings.

223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Bell Investment Advisors held 15 shares of Edgewise Therapeutics worth $610 as of Q2 2026.
  • Edgewise Therapeutics was a new Bell Investment Advisors position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1669 holding.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.